Google Ad

The Biotech Anapysbio $ANAB was the best performing stock in America for 2017. The Biotech was 1 of 8 Biotechs that made up the Top 10 stocks in the year. The stock doubled following the announcement of its eczema drug tests.

ANAB Daily

ANAB Doubled in Value After A Successful Drug Announcement

AnaptysBio went public at 15 a share and closed out the year over $100. A spectacular rise by any measure.

Looking forward analysts are expecting a loss of $1.71 per share for 2017 and a further loss $2.46 of a share in 2018. Investors are betting on the future of this biotech.

What Doubled ANAB in October?

In October, the company reported positive proof-of-concept data for ANB020, its investigational anti-IL-33 therapeutic antibody, in an ongoing Phase 2a clinical trial in adult patients with moderate-to-severe atopic dermatitis.

After a single dose of ANB020, 75 percent of patients achieved an Eczema Area Severity Index (EASI) score improvement of 50 percent relative to enrollment baseline (EASI-50) at day 15, 83 percent of patients achieved EASI-50 at day 29 and 75 percent of patients achieved EASI-50 at day 57. All 12 patients achieved EASI-50 at one or more time points through Day 57 post-ANB020 administration. ANB020 was generally well tolerated in all patients as of this interim analysis.

During the first half of 2018, AnaptysBio plans to initiate a Phase 2b randomized, double-blinded, placebo-controlled study in 200-300 adult patients with moderate-to-severe atopic dermatitis to evaluate multi-dose subcutaneous administration of ANB020, with data expected in 2019.

About AnaptsBio

AnaptysBio is a clinical-stage antibody development company advancing therapeutic antibody product candidates focused on unmet medical needs in inflammation. Has a proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, or SHM, and replicates this natural process of antibody generation in vitro.

Their strategy is to advance the development and commercialization of proprietary product candidates, and for certain programs, establish partnerships with leading biopharmaceutical companies where we retain certain development and commercialization rights in the United States. ANAB's wholly-owned product pipeline includes ANB020 and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need.  $ANAB is advancing their ANB020 product candidate, an antibody that inhibits the activity of interleukin-33, for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy and severe adult eosinophilic asthma.

In addition the company is  developing our ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustular psoriasis (PPP).


ANAB Pipeline

Source: AnaptysBio

Live From The Pit

Log in to comment
Discuss this article in the forums (1 replies).